Register for our free email digests:
Bausch + Lomb Inc.
http://www.bausch.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bausch + Lomb Inc.
After NDA Investment For OTC Switch, Success Swings On More Spending For Advertising
Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.
US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Company Information
- Other Names / Subsidiaries
-
- Bausch & Lomb
- Bausch + Lomb Technolas
- ISTA Pharmaceuticals, Inc. (ISTA)
- Laboratorio Pförtner Cornealent SACIF, Waicon
- Technolas Perfect Vision GmbH